Previous 10 | Next 10 |
Zai Lab obtains the right to develop and exclusively commercialize adagrasib in mainland China, Hong Kong, Macau and Taiwan Mirati to receive an upfront payment of $65 million, up to approximately $273 million in potential milestone payments and high-teen- to low-twenties-percent ...
Mirati Therapeutics and Zai Lab Enter Into a Collaboration to Develop and Commercialize Adagrasib in Greater China - Zai Lab obtains the right to develop and exclusively commercialize adagrasib in China, Hong Kong, Macau and Taiwan - Mirati to receive an upfront payment of $...
Amgen (AMGN) and Mirati Therapeutics' (MRTX) just approved KRAS inhibitor Lumakras (sotorasib) for non-small cell lung cancer ("NSCLC") could be used with as many as 13% of those patients.Lumakras is specifically approved for NSCLC patients with the KRAS G12C generic mutation who have failed ...
Amgen ([[AMGN]] +1.4%) and Mirati Therapeutics ([[MRTX]] +2.5%) are trading higher on the news of FDA approval for Lumakras (sotorasib) on priority review as a treatment for adults with non-small cell lung cancer ((NSCLC)).A once-daily oral small molecule, Lumakras is now indicated in a secon...
QIAGEN N.V. (QGEN) announces a global collaboration with Mirati Therapeutics (MRTX) to continue developing a tissue-based KRAS companion diagnostic to identify certain patients with cancers that have a KRASG12C mutation.The diagnostic aims to identify patients with the conditio...
KRAS mutations in NSCLC reflect a large underserved patient population with an unmet need for innovative treatment options QIAGEN is developing a tissue-based companion diagnosticin support of adagrasib, Mirati’s investigational selective KRAS G12C inhibitor ...
Analysts remain bullish on Travere despite approval of Thiola genericTravere Therapeutics (TVTX) fell sharply in mid-day trading Friday on the news of FDA approval for a Thiola (tiopronin) generic. A late recovery ensured the stock was only ~3.3% lower by the close.The Wall Street a...
Mirati Therapeutics (MRTX): Q1 GAAP EPS of -$2.67 misses by $0.54.Cash, cash equivalents, and short-term investments of $1.29BPress Release For further details see: Mirati Therapeutics EPS misses by $0.54
Mirati Therapeutics Reports First Quarter 2021 Financial Results and Recent Corporate Updates - Initiated potentially registration-enabling trials evaluating our investigational KRASG12C inhibitor, adagrasib, in lung and colorectal cancers, as monotherapy and with other agents ...
With a flurry of ongoing clinical studies, you can bet that Mirati has much more catalysts to power further upsides. As a KRAS inhibitor, Adagrasib is generating robust data for a variety of cancers, including lungs, colorectal, pancreatic, etc. Sitravatinib is the other lead medi...
News, Short Squeeze, Breakout and More Instantly...
Mirati Therapeutics Inc. Company Name:
MRTX Stock Symbol:
NASDAQ Market:
Mirati Therapeutics Inc. Website:
First Solar Inc. (FSLR) is expected to report $3.19 for Q4 2023 VIZIO Holding Corp. Class A (VZIO) is expected to report $0.02 for Q4 2023 Henry Schein Inc. (HSIC) is expected to report $0.71 for Q4 2023 Republic Services Inc. (RSG) is expected to report $1.28 for Q4 2023 Forge Gl...
European Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation PR Newswire SAN DIEGO and ZUG, Switzerland , Jan. 10, 2024 /PRNewswire/ -- Mirati The...
2023-12-18 23:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...